letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...678910111213141516...99100»
  • ||||||||||  letrozole / Generic mfg.
    Multiplex cytokine profiling of stimulated splenocytes from the letrozole-induced PCOS mouse model (Exhibit Hall F1; Poster Board Number: B932) -  Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2512;    
    Altogether, the decrease in pro-inflammatory cytokines may be linked to the likelihood of increased testosterone levels, as presented in previous studies on LET-treated female mice. Testosterone has immunomodulatory properties, but the biological process involved needs further investigation to determine the efficiency of using murine models to study inflammation in PCOS.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    New P2 trial, Mismatch repair, Metastases:  ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab (clinicaltrials.gov) -  Apr 15, 2024   
    P2,  N=76, Not yet recruiting, 
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Gene Expression in Porcine Bulbourethral Glands. (Pubmed Central) -  Apr 13, 2024   
    Gene expression for these two key proteins in androgen signaling was quite low during the initial allometric growth in the late juvenile and prepuberal intervals, suggesting that this initial growth was not primarily stimulated by androgens. These observations are consistent with a more direct estrogen-mediated inhibition of growth via GPER previously proposed, with the sensitivity extending into the late juvenile interval when estrogens as well as androgens are normally relatively low.
  • ||||||||||  hydrocortisone / Generic mfg., flutamide / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Apr 8, 2024   
    P4,  N=62, Active, not recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    New trial, HEOR:  Breast Cancer & Antiestrogenic Therapy & Brain (clinicaltrials.gov) -  Apr 4, 2024   
    P=N/A,  N=180, Not yet recruiting, 
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment open, Trial initiation date:  RADIANT: Pre-op Radiation With Abemaciclib and Letrozole (clinicaltrials.gov) -  Apr 3, 2024   
    P1,  N=15, Recruiting, 
    NCT05872204. Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Jun 2024
  • ||||||||||  Prolia (denosumab) / Amgen, Kadcyla (ado-trastuzumab emtansine) / Roche
    Journal, Metastases:  Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. (Pubmed Central) -  Mar 29, 2024   
    It is possible that antitumor drugs affect calcium and bone metabolism associated with bone metastases. While these cases are rare, it is crucial for oncologists to be aware of hypocalcemia not only at the initiation of bone-modifying agents but also throughout the entire antitumor therapy, as hypocalcemia can lead to fatal outcomes.
  • ||||||||||  letrozole / Generic mfg.
    Biomarker, Journal:  Intrauterine insemination: prognostic factors. (Pubmed Central) -  Mar 28, 2024   
    In this study, the ovulation induction protocol with gonadotropins plus letrozole and post-capacitation progressive sperm ? 5 million/mL were the only variables that significantly correlated with intrauterine insemination success.
  • ||||||||||  Retrospective data, Review, Journal:  Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Mar 28, 2024   
    Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Neonatal aromatase inhibition blocked defeminization of AVPV Kiss1 neurons and LH surge-generating system in male rats. (Pubmed Central) -  Mar 27, 2024   
    The results of the present study showed that the neonatal administration of letrozole (LET), a nonsteroidal aromatase inhibitor, within 2?hours of birth rescued AVPV Kiss1 expression and the LH surge in adult male rats, while the neonatal administration of testosterone propionate (TP) irreversibly attenuated AVPV Kiss1 expression and the LH surge in adult female rats...Moreover, neonatal TP administration significantly decreased the number of arcuate (ARC) Kiss1-expressing and Kiss1-Cre-activated tdTomato-positive cells and suppressed LH pulses in adult gonadectomized female rats; however, neonatal LET administration failed to affect them. These results suggest that E2 converted from neonatal testosterone is primarily responsible for the defeminization of AVPV kisspeptin neurons and the subsequent GnRH/LH surge generation in male rats.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) -  Mar 25, 2024   
    Initiation date: Feb 2024 --> Oct 2023 A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Phase classification:  A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) -  Mar 25, 2024   
    P1,  N=198, Active, not recruiting, 
    A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38 Phase classification: P1b --> P1
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluation of IM Letrozole ISM (clinicaltrials.gov) -  Mar 25, 2024   
    P1,  N=120, Active, not recruiting, 
    Phase classification: P1b --> P1 Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Journal:  Ribociclib plus Endocrine Therapy in Early Breast Cancer. (Pubmed Central) -  Mar 24, 2024   
    P3
    Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
  • ||||||||||  letrozole / Generic mfg., desmopressin / Generic mfg.
    Central diabetes Insipidus of unknown etiology () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_977;    
    She was on fertility treatment with letrozole for five (5 ) days prior to presentation and had noticed an increase in urinary frequency and increased thirst. This case highlights the need to consider idiopathic CDI in patients presenting with polyuria and polydipsia in the absence of any obvious causes including trauma, surgery, autoimmune disorder as timely diagnosis and treatment may significantly improve their quality of life.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal:  A rare case of Takotsubo cardiomyopathy. (Pubmed Central) -  Mar 22, 2024   
    This case highlights the need to consider idiopathic CDI in patients presenting with polyuria and polydipsia in the absence of any obvious causes including trauma, surgery, autoimmune disorder as timely diagnosis and treatment may significantly improve their quality of life. Pharmacovigilance and experimental studies are warranted to confirm any causative relationship and to explore the underlying pathophysiology, respectively.
  • ||||||||||  Navigating Sexuality and Hormone Therapy in Early Luminal Breast Cancer (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_527;    
    Our study shows the strong link between sexual dysfunction and HT in Luminal eBC. This AEs emphasize the need for tailored support, personalized approaches and integrated sexual counseling, improving patients QoL and outcomes.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: is it predictive of outcome? (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_479;    
    As for the endocrine compound, 240 pts were treated with letrozole, and 112 pts with fulvestrant... HER2-low status, albeit being predictive for subsequent anti-HER2 treatment modalities, was not predictive for PFS nor OS in advanced breast cancer patients treated with CDK4/6 inhibitors.
  • ||||||||||  Comparison of Response with Chemotherapy vs Endocrine Therapy and its Association with Ki67 in Hormone Receptor Positive Metastatic Breast Cancer (Exhibition area) -  Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_477;    
    Patients eligible for the study were offered hormone therapy (Tamoxifen 20mg daily in premenopausal and letrozole 2.5mg daily for post-menopausal women) or chemotherapy (single agent doxorubicin 60mg/m2 every 3 weeks for 4 cycles or single agent paclitaxel 175mg/m2 every 3 weeks for 4 cycles) after randomization into both groups. Ki67 scores can help stratify the patients to identify those who will gain the most benefit from either treatment approach as shown in our study where high Ki67 scores are correlated with significantly better responses with chemotherapy and hormonal therapy offered better responses in low Ki67 subset.